LMTK3 and triple-negative breast carcinoma: Likewise, given the aberrant expression of LMTK3 in triple negative breast cancer (TNBC) and studies showing that LMTK3 inhibition results in inhibition of TNBC cell proliferation, migration and invasion [14,16,17], the use of LMTK3 inhibitors could have beneficial effects for this clinically unmet category of BC patients.